Development of influenza A antivirals

摘要

The present invention includes compositions, methods and systems to isolate and characterize novel antiviral agents by contacting the antiviral agent with the F2F3 zinc fingers of a CPSF30 protein and an Influenza A NS1A protein; and determining whether the binding between the CPSF30 protein and the Influenza A NS1A protein is reduced.

主权项

1. A method of inhibiting Influenza A replication comprising:
providing a pharmaceutical preparation comprising: (a) a pharmaceutical carrier and (b) a F2F3 zinc finger construct, wherein said construct is a fragment of a cleavage and polyadenylation specificity factor 30 kDa subunit (CPSF30) protein comprising a F2F3 zinc finger, or a polynucleotide construct encoding such a fragment, wherein the fragment inhibits Influenza A NS1A protein-mediated reduction of interferon-α and/or interferon-β and does not inhibit 3′ end processing of cellular pre-mRNAs; administering an effective amount of the pharmaceutical preparation to one or more cells infected by influenza A virus; thus allowing the F2F3 zinc finger fragment to bind with and inhibit Influenza A NS1A protein activity and thus inhibiting Influenza A virus replication.